H.C. Wainwright analyst Oren Livnat raised the firm’s price target on MannKind (MNKD) to $7 from $6 and keeps a Buy rating on the shares post the Q4 results. The analyst says "rapid" Tyvaso DPI royalty growth brings "breakeven within sight" for the company. In addition, MannKind shares "should be backstopped by the ever-present prospect" of a bid from United Therapeutics (UTHR), the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNKD:
- MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
- MannKind to present results from study of inhaled Technosphere Insulin
- MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
- MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
- Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
